Ethereum's Decline Triggers Massive Sell-Off in 180 Life Sciences Stock
PorAinvest
viernes, 15 de agosto de 2025, 12:32 pm ET1 min de lectura
ATNF--
The company holds 82,186 ETH, valued at approximately $349 million, and plans to rebrand as ETHZilla Corporation. The recent surge in ATNF's stock can be attributed to the company's Ethereum treasury strategy, which involves accumulating ETH to become a benchmark for on-chain treasury management among public companies. The strategy aims to generate cash flow for shareholders through a differentiated yield generation program facilitated by a partnership with Electric Capital.
Despite the recent gains, the stock's after-hours decline reflects the broader market's reaction to Ethereum's price drop. The company's stock has seen a year-to-date increase of 83.52% and a 91.95% rise over the past 12 months. The recent announcement has led to heavy trading, with approximately 33 million shares changing hands on July 2, 2025, compared to a three-month average of about 4.78 million units.
Billionaire venture capitalist Peter Thiel holds a 7.5% stake in the firm, adding further credibility to the company's strategy. The company's treasury strategy is part of its broader evolution from a biotechnology company to a software-enabled gaming and entertainment enterprise.
References:
[1] https://finance.yahoo.com/news/180-life-sciences-ethzilla-holds-120000891.html
[2] https://www.ainvest.com/news/180-life-sciences-stock-plunges-ethereum-decline-2508/
ETH--
180 Life Sciences Corp. (ATNF) shares slid 1.45% in after-hours trading, coinciding with the decline of Ethereum (ETH). ETH's decline triggered a 28% decline in ATNF's stock during the regular trading session. ATNF has been on a tear lately, surging as much as 116% in a week and 755% in a month, aligning with ETH's rise in this period. The company holds 82,186 ETH, valued at over $381 million, and plans to rebrand as ETHZilla Corporation.
180 Life Sciences Corp. (ATNF) shares experienced a significant decline of 28% during the regular trading session on July 2, 2025, coinciding with a 3.38% increase in Ethereum's (ETH) price to $4,431 over a 24-hour period. The stock's after-hours trading saw a 1.45% drop, reflecting the broader market's reaction to Ethereum's price drop. The biotechnology company's stock has surged 116% in a week and 755% in a month, aligning with ETH's rise during this period.The company holds 82,186 ETH, valued at approximately $349 million, and plans to rebrand as ETHZilla Corporation. The recent surge in ATNF's stock can be attributed to the company's Ethereum treasury strategy, which involves accumulating ETH to become a benchmark for on-chain treasury management among public companies. The strategy aims to generate cash flow for shareholders through a differentiated yield generation program facilitated by a partnership with Electric Capital.
Despite the recent gains, the stock's after-hours decline reflects the broader market's reaction to Ethereum's price drop. The company's stock has seen a year-to-date increase of 83.52% and a 91.95% rise over the past 12 months. The recent announcement has led to heavy trading, with approximately 33 million shares changing hands on July 2, 2025, compared to a three-month average of about 4.78 million units.
Billionaire venture capitalist Peter Thiel holds a 7.5% stake in the firm, adding further credibility to the company's strategy. The company's treasury strategy is part of its broader evolution from a biotechnology company to a software-enabled gaming and entertainment enterprise.
References:
[1] https://finance.yahoo.com/news/180-life-sciences-ethzilla-holds-120000891.html
[2] https://www.ainvest.com/news/180-life-sciences-stock-plunges-ethereum-decline-2508/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios